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Avocado/soybean unsaponiﬁable (ASU) to treat osteoarthritis:
a clariﬁcationToday, a cure for osteoarthritis (OA) remains elusive and
the management of OA is largely palliative focussing on
the alleviation of symptoms. Current recommendations for
the management of OA include a combination of non-
pharmacological interventions and pharmacological treat-
ments1e3. Until now, the pharmacological management of
OA is dominated by non-steroidal anti-inﬂammatory drugs
and analgesic (mainly paracetamol). Beside these conven-
tional drugs, some new compounds classiﬁed as Symptom-
atic Slow Acting Disease Modifying drugs (SYSADOAs)
have shown symptomatic efﬁcacy in human hip and knee
OA. The term SYSADOA covers a range of agents, includ-
ing glucosamine sulphate, chondroitin sulphate, diacerhein,
hyaluronic acid and avocado/soybean (A/S) unsaponiﬁ-
ables (ASUs), components of PIASCLEDINE300 (Labora-
tories Expansciences, Courbevoie, France). The original
ASUs are recommended for the treatment of OA symptoms
by the American College of Rheumatology (ACR) and by
European League Against Rheumatism (EULAR). These
recommendations have been elaborated on the basis of
clinical, animal and in vitro studies performed with
PIASCLEDINE300 (Laboratories Expansciences, Courbe-
voie, France). PIASCLEDINE300 has been used in
France as a prescription treatment for OA, subsidized by
the government and meticulously tracked for safety for
over 15 years. PIASCLEDINE300 pill is composed by
100 mg of avocado unsaponiﬁables and 200 mg of soybean
unsaponiﬁables. The originality is based on the A/S ratio
and avocado speciﬁc modiﬁed unsaponiﬁables obtained
by a patented process. In other countries, ASUs are deliv-
ered as over-the-counter products.
At this time, there are three well-conducted, randomized,
placebo-controlled, trials demonstrating a beneﬁcial symp-
tomatic effect of PIASCLEDINE300 in the treatment of
hip and/or knee OA4e6. Until now, only the ASUs found in
PIASCLEDINE300 have demonstrated their clinical efﬁ-
ciency. Further, we have demonstrated that in vitro, PIA-
SCLEDINE300 displayed anabolic, anti-catabolic and
anti-inﬂammatory effects on human chondrocytes. It
increased the basal synthesis of aggrecan and reversed
the interleukin (IL)-1b-induced reduction of aggrecan syn-
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of stromelysin-1 [matrix metalloproteinase (MMP-3)], IL-6
and -8, and prostaglandin E2 (PGE2) while it weakly re-
versed the IL-1-induced decrease of tissue inhibitor of met-
alloprotease’s (TIMP)-1 production7,8. It also decreased the
spontaneous production of the macrophage inﬂammatory
protein (MIP)-1b but stimulated the production of transform-
ing growth factor (TGF)-b17. Finally, this drug fully pre-
vented the inhibitory effect of OA osteoblasts on cartilage
matrix protein production by human chondrocytes9. All of
this clearly demonstrates the therapeutic and biological ef-
fects of the ASU from PIASCLEDINE300.
Recently, Au et al.10 have demonstrated that an ASU ex-
tract, named ASU-NMX 1000 (Nutramax Laboratories Inc,
Edgewood, MD, USA) suppressed tumour necrosis factor
(TNF)-a, IL-1b, cyclooxygenase (COX)-2 and inducible
nitric oxide (iNOS) gene expression, and PGE2 and nitric
oxide production in articular chondrocytes and monocyte/
macrophages. They conclude that these observations pro-
vide a scientiﬁc rationale for the pain-reducing and anti-
inﬂammatory effects of ASU observed in OA patients. In
other terms, the authors attempt to explain the therapeutic
effect of PIASCLEDINE300 by in vitro effects obtained
with another ASU extract which shows a different chromato-
graphic spectrum. Lippielo et al. (Nutramax Laboratories)
have recently demonstrated that, compared to ASU-NMX
1000, PIASCLEDINE300 contains three major addi-
tional peaks11. These peaks result of the particular extr-
action process used to prepare PIASCLEDINE300. In
comparison with PIASCLEDINE300, other ASU formula-
tions showed almost the complete absence of speciﬁc mol-
ecules which are patented. Therefore, while the ability of
ASU-NMX 1000 and PIASCLEDINE300 to reduce
PGE2 production or MMP activity or to stimulate glycosami-
noglycans seems to be comparable11, different effects of
these two formulations on other aspects of the chondrocyte
metabolism can not be excluded. Therefore, to extrapolate
the data obtained with one ASU formulation to another
one remains fully speculative. Further, clinical studies are
required before concluding on the safety and the clinical ef-
ﬁcacy of ASU-NMX 1000. To use the in vitro and clinical
data obtained with PIASCLEDINE300 to support a poten-
tial effect of ASU-NMX 1000 must be done with a great
caution.Y. Henrotin, Ph.D., Professor*
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University of Lie`ge Institute of Pathology, Belgium
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